Reduced Risk of Progression from Non-Severe to Severe COVID-19 in Hospitalized Dialysis Patients by Full COVID-19 Vaccination

被引:3
|
作者
Ichii, Mitsuru [1 ]
Kurajoh, Masafumi [2 ]
Okute, Yujiro [1 ]
Ihara, Yasutaka [3 ]
Imai, Takumi [3 ]
Morioka, Tomoaki [2 ]
Mori, Katsuhito [4 ]
Shoji, Tetsuo [5 ]
Tsujimoto, Yoshihiro [1 ]
Ubai, Takanobu [6 ]
Emoto, Masanori [2 ,4 ]
机构
[1] Inoue Hosp, Dialysis Ctr, Div Internal Med, Suita, Osaka 5640053, Japan
[2] Osaka Metropolitan Univ, Dept Metab Endocrinol & Mol Med, Grad Sch Med, Osaka 5458585, Japan
[3] Osaka Metropolitan Univ, Dept Med Stat, Grad Sch Med, Osaka 5458585, Japan
[4] Osaka Metropolitan Univ, Dept Nephrol, Grad Sch Med, Osaka 5458585, Japan
[5] Osaka Metropolitan Univ, Dept Vasc Med, Grad Sch Med, Osaka 5458585, Japan
[6] Inoue Hosp, Dept Urol, Suita, Osaka 5640053, Japan
关键词
COVID-19; full vaccination; severe progression; dialysis patients; HEMODIALYSIS;
D O I
10.3390/jcm11216348
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronavirus disease 2019 (COVID-19) vaccination reduces the risk of progression to severe COVID-19 in the general population. To examine that preventive effect in dialysis patients, the association of vaccination status with severe COVID-19 progression was investigated in this retrospective observational study conducted from December 2020 to May 2022 of 100 such patients hospitalized for non-severe COVID-19 at Inoue Hospital (Suita, Japan). Fifty-seven were fully vaccinated, defined as receiving a COVID-19 vaccine second dose at least 14 days prior to the onset of COVID-19, while 43 were not. Among all patients, 13 (13.0%) progressed to severe COVID-19 with a median (interquartile range) time of 6 (2.5-9.5) days, while 87 (87.0%) were discharged after 11 (8-16) days. Kaplan-Meier analysis showed that fully vaccinated patients had a significantly lower rate of progression to severe COVID-19 (p = 0.001, log-rank test). Cox proportional hazard analysis also indicated that full COVID-19 vaccination was significantly associated with reduced instances of progression to severe COVID-19 (hazard ratio 0.104, 95% confidence interval 0.022 to 0.483; p = 0.004) after balancing patient background characteristics using an inverse probability of treatment weight method. These results suggest that full vaccination status contributes to reducing the risk of progression from non-severe to severe COVID-19 in dialysis patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Biochemical Risk Factors of Atherosclerosis in Patients with Severe and Non-severe COVID-19
    Shahali, Maryam
    Alamdary, Ashkan
    Gholami, Alireaza
    Moukhah, Rasul
    Mousavi-Nasab, Seyed Dawood
    Tehrani, Mohammad Javad Hossein
    Mardani, Rajab
    Ahmadi, Nayebali
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2024, 19 (04):
  • [2] Association between vaccination and days of hospitalization in adult patients with non-severe COVID-19
    Ding, Xiao
    Ye, Jiru
    Tang, Yao
    Zhu, Feng
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2024, 18 (01): : 34 - 43
  • [3] Home Management of COVID-19 Patients: A Successful Model in Non-severe COVID-19 Patients in the Developing World
    Alishan, Syed
    Ali, Farheen
    Iqbal, Zafar
    Ammar, Ali
    Muhammad, Atif S.
    Farooq, Faiza
    Mir, Ayaz
    Salahuddin, Nawal
    Saghir, Tahir
    Karim, Musa
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (01)
  • [4] COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination
    Stevens, Hannah
    Ruiz-Carmona, Sergio
    Peter, Karlheinz
    McFadyen, James D.
    HAEMATOLOGICA, 2023, 108 (09) : 2503 - 2506
  • [5] COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination
    Stevens, Hannah
    Ruiz-Carmona, Sergio
    Peter, Karlheinz
    Mcfadyen, James D.
    REVISTA CHILENA DE LITERATURA, 2023, (108): : 2503 - 2506
  • [6] Antibody therapies for treatment of non-severe COVID-19
    Gourlay, Katie
    Taylor, Nicholas
    Lang, Eddy
    INTERNAL AND EMERGENCY MEDICINE, 2022, 17 (03) : 883 - 885
  • [7] Antibody therapies for treatment of non-severe COVID-19
    Katie Gourlay
    Nicholas Taylor
    Eddy Lang
    Internal and Emergency Medicine, 2022, 17 : 883 - 885
  • [8] Corticosteroids for Non-severe COVID-19: Primum Non Nocere
    Muthu, Valliappan
    Sehgal, Inderpaul S.
    Dhooria, Sahajal
    Prasad, Kuruswamy Thurai
    Aggarwal, Ashutosh N.
    Agarwal, Ritesh
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2022, 26 (03) : 402 - 403
  • [9] Clinical Characteristics and Analysis of Associated Risk Factors in Patients with Severe and Non-Severe COVID-19 Infection
    Zhou, Yong
    Wang, Zhen
    Chen, Fei
    Xiong, Ying-Xia
    Wang, Wei
    Huang, Jun -Min
    Fang, Wei
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 1539 - 1544
  • [10] Are CLD Patients at increased Risk for severe COVID-19 Progression?
    Metzger, Leandra
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (12): : 1258 - +